Related Experiment Video

Updated: Sep 14, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.2K

Editorial: Target organ damage in Fabry disease

Guido Iaccarino1, Francesca Graziani2

  • 1Department of Clinical Medicine and Surgery, Federico II University, Napoli, Italy.

Frontiers in Cardiovascular Medicine
|July 23, 2025
PubMed
Summary

No abstract available in PubMed .

Keywords:
Fabry diseasegeneticsmechanismstarget organ damagetreatment

More Related Videos

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
07:45

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

3.5K
Cell Type-specific Gene Expression Profiling in the Mouse Liver
10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

7.8K

Related Experiment Videos

Last Updated: Sep 14, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.2K
Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
07:45

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

3.5K
Cell Type-specific Gene Expression Profiling in the Mouse Liver
10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

7.8K

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

46
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
46

Articles linked to this work by shared authors, journal, and citation graph.

Cardiological aspects of Fabry disease: from diagnosis to therapeutic efficacy assessment.

Orphanet journal of rare diseases·2026

Left atrioventricular coupling index in transthyretin amyloid cardiomyopathy: Association with mortality.

International journal of cardiology·2026

Percutaneous treatment of pulmonary vein stenosis: a transoesophageal echocardiography step-by-step guide in diagnosis and treatment.

European heart journal. Imaging methods and practice·2026

DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

Digital Solutions for the Control of Lifestyle Parameters in Individuals With High Cardiometabolic Risk: a Scoping Review.

Current nutrition reports·2026

Early mitophagy defects and impaired mitochondrial energy metabolism drive target organ damage progression: lessons from the Fabry heart.

bioRxiv : the preprint server for biology·2026

Case Report: Discordant high-sensitivity cardiac troponin T elevation in polymyositis: a diagnostic pitfall.

Frontiers in cardiovascular medicine·2026

Angiotensin II-driven coronary vasculopathy and pressure-overload myocardial remodeling represent distinct vascular phenotypes.

Frontiers in cardiovascular medicine·2026

Traumatic brain injury in patients with mechanical heart valves on lifelong anticoagulation: incidence, management, and outcomes of intracranial hemorrhage.

Frontiers in cardiovascular medicine·2026

Metabolic reprogramming in radiation-induced heart disease: the emerging role of PET imaging.

Frontiers in cardiovascular medicine·2026

Preoperative identification and multidisciplinary management of von Willebrand disease in atrial septal defect closure: a case report.

Frontiers in cardiovascular medicine·2026

Genetic liability to childhood Kawasaki disease and adult cardiovascular outcomes.

Frontiers in cardiovascular medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us